Spontaneous reports of primarily suspected herbal hepatotoxicity by Pelargonium sidoides: Was causality adequately ascertained?

Regulatory Toxicology and Pharmacology

Volumn 63, Issue 1, 2012, Pages 1-9

  Teschke, Rolf ^a   Frenzel, Christian ^b   Schulze, Johannes ^c   Eickhoff, Axel ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c GOETHE UNIVERSITY MEDICAL SCHOOL   (Germany)

Author keywords

Herb induced liver injury; Herbal hepatotoxicity; Pelargonium sidoides; Pelargonium sidoides questionable hepatotoxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; HERBACEOUS AGENT; UMCKALOABO;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CAUSAL ATTRIBUTION; CHILD; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; COUNCIL FOR INTERNATIONAL ORGANIZATION OF MEDICAL SCIENCES SCALE; DRUG INDICATION; DRUG OVERDOSE; EVIDENCE BASED MEDICINE; FEMALE; HERBAL MEDICINE; HUMAN; LIVER INJURY; LIVER TOXICITY; MALE; OUTCOME ASSESSMENT; PELARGONIUM; PELARGONIUM SIDOIDES; PRESCHOOL CHILD; PRIORITY JOURNAL; RATING SCALE; RESPIRATORY TRACT INFECTION; SCHOOL CHILD; SEX RATIO; TREATMENT DURATION; VIRUS INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASES; CHILD; CHILD, PRESCHOOL; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; PELARGONIUM; PLANT PREPARATIONS; YOUNG ADULT;

HUMAN HERPESVIRUS 3; HUMAN HERPESVIRUS 4; PELARGONIUM SIDOIDES; SIMPLEXVIRUS;

EID: 84858259901     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2012.02.009     Document Type: Article

References (28)

1. Agarwal V.K., McHutchison J.G., Hoofnagle J.H. Drug-Induced Liver Injury Network (DILIN). Important elements for the diagnosis of drug-induced liver injury. Clin. Gastroenterol. Hepatol. 2010, 8:463-470.
2. Andrade, R.J., Lucena, M.I., Fernández, M.C., Pelaez, G., Pachkoria, K., García-Ruiz, E., García-Muñoz, B., Gonzalez-Grande, R., Pizarro, A., Durán, J.A., Jiménez, M., Rodrigo, L., Romero-Gomez, M., Navarro, J.M., Planas, R., Costa, J., Borras, A., Soler, A., Salmerón, J., Martin-Vivaldi, R., Spanish Group for the Study of Drug-induced Liver Disease, 2005. Drug-induced liver injury. An analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 129, 512-521.
3. Au J.S., Navarro V.J., Rossi S. Review article: drug induced liver injury - its pathophysiology and evolving diagnostic tools. Aliment. Pharmacol. Ther. 2011, 34:11-20.
4. Bénichou C., Danan G., Flahault A. Causality assessment of adverse reactions to drugs - II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J. Clin. Epidemiol. 1993, 46:1331-1336.
5. Danan G., Bénichou C. Causality assessment of adverse reactions to drugs - I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J. Clin. Epidemiol. 1993, 46:1323-1330.
6. DCGMA, 2011. Drug Commission of the German Medical Association (Arzneimittelkommission der Deutschen Ärzteschaft). Hepatitis in connection with Umckaloabo®. Deutsches Ärzteblatt 108, C1399-C1400 (Article in German).
7. EMA, 2011. European Medicines Agency: Assessment report on Pelargonium sidoides DC and/or Pelargonium reniforme Curt., radix. Issued March 31, 2011. Available at: (accessed 11.02.12). http://www.ema.europa.eu/docs/en_GB/document_library/Herbal_-_HMPC_assessment_report/2011/06/WC500107717.pdf.
8. Estes J.D., Stolpman D., Olyaei A., Corless C., Ham J.M., Schwartz J.M., Orloff S.L. High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failure. Arch. Surg. 2003, 138:852-858.
9. García-Cortés M., Lucena M.I., Pachkoria K., Borraz Y., Hidalgo R., Andrade R.J. Evaluation of Naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury. Aliment. Pharmacol. Ther. 2008, 27:780-789.
10. Gill R., Sterling R. Acute liver failure. J. Clin. Gastroenterol. 2001, 33:191-198.
11. Gunawan B., Kaplowitz N. Clinical perspectives on xenobiotic-induced hepatotoxicity. Drug Metab. Rev. 2004, 36:301-312.
12. Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology 2001, 33:308-310.
13. Liss G., Lewis J.H. Drug-induced liver injury: what was new in 2008?. Expert. Opin. Drug Metab. Toxicol. 2009, 5:843-860.
14. Mason A., Sallie R. What causes fulminant hepatic failure of unknown etiology?. Am. J. Clin. Pathol. 1995, 104:491-494.
15. Navarro V.J. Herbal and dietary supplement hepatotoxicity. Semin. Liver Dis. 2009, 29:373-382.
16. Rochon, J., Protiva, P., Seeff, L.B., Fontana, R.J., Liangpunsakul, S., Watkins, P.B., Davern, T., McHutchison, J.G., for the Drug-Induced Liver Injury Network (DILIN), 2008. Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology 48, 1175-1183.
17. Rockey, D.C., Seeff, L.B., Rochon, J., Freston, J., Chalasani, N., Bonachini, M., Fontana, R.J., Hayashi, P.H., for the US Drug-induced Liver Injury Network, 2010. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology 51, 2117-2126.
18. Seeff L.B. Herbal hepatotoxicity. Clin. Liv. Dis. 2007, 11:577-596.
19. Shakil A.O., Kramer D., Mazariegos G.V., Fung J.J., Rakela J. Acute liver failure: clinical features, outcome analysis, and applicability of prognostic criteria. Liver Transpl. 2000, 6:163-169.
20. Stine J.G., Lewis J.H. Drug-induced liver injury: a summary of recent advances. Expt. Opin. Drug Metab. Toxicol. 2011, 7:875-890.
21. Teschke R. Hepatotoxicity by drugs and dietary supplements: safety perspectives on clinical and regulatory issues. Ann. Hepatol. 2009, 8:184-195.
22. Teschke R., Bahre R. Severe hepatotoxicity by Indian Ayurvedic herbal products: a structured causality assessment. Ann. Hepatol. 2009, 8:258-266.
23. Teschke R., Wolff A. Regulatory causality evaluation methods applied in kava hepatotoxicity: are they appropriate?. Regul. Tox. Pharmacol. 2011, 59:1-7.
24. Teschke R., Schwarzenboeck A., Hennermann K.H. Causality assessment in hepatotoxicity by drugs and dietary supplements. Br. J. Clin. Pharmacol. 2008, 66:758-766.
25. Teschke R., Schwarzenboeck A., Hennermann K.H. Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases. Eur. J. Gastroenterol. Hepatol. 2008, 20:1182-1193.
26. Teschke R., Glass X., Schulze J. Herbal hepatotoxicity by Greater Celandine (Chelidonium majus): causality assessment of 22 spontaneous reports. Regul. Toxicol. Pharmacol. 2011, 61:282-291.
27. Teschke R., Schwarzenboeck A., Schmidt-Taenzer W., Wolff A., Hennermann K.H. Herb induced liver injury presumably caused by black cohosh: a survey of initially purported cases and herbal quality specifications. Ann. Hepatol. 2011, 11:249-259.
28. WHO, 2000. World Health Organization. Causality assessment of suspected adverse reactions. WHO Collaboratoring Centre for International Drug Monitoring (Uppsala Monitoring Centre, UMC), Database. Available at: (accessed 11.02.12). http://www.who-umc.org/DynPage.aspx?id=22682.